The role of CD40 in peripheral T cell tolerance and immunity

Journal of Molecular Medicine

Volumn 78, Issue 7, 2000, Pages 363-371

  Diehl, L ^a   Den Boer, A T ^a   Van Der Voort, E I H ^a   Melief, C J M ^a   Offringa, R ^a   Toes, R E M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CD40 CD40; Cytotoxic T Lymphocyte; Dendritic cell; T cell immunity; T cell tolerance; T helper cell

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD28 ANTIGEN; CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN GP 39; LYMPHOCYTIC CHORIOMENINGITIS VIRUS DERIVED PEPTIDE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MOLECULAR INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033830353     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090000126     Document Type: Review

References (75)

1. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay
2. The effect of allogeneic presensitization on H-Y graft survival and in vitro cell-mediated responses to H-y antigen
3. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target
4. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
5. A reassessment of the role of B7-1 expression in tumor rejection
6. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells
7. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells
8. Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation
9. TAP1-independent loading of class I molecules by exogenous viral proteins
10. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96
11. Heat shock proteins transfer peptides during antigen processing and CTL priming
12. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides
13. Cross-presentation of gp96-associated antigens on MHC class I molecules requires receptor-mediated endocytosis
14. Cross-priming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells
15. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
16. Natural adjuvants: Endogenous activators of dendritic cells
17. Mechanisms of antigen uptake for presentation
18. The endocytic activity of dendritic cells
19. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses
20. Developmental regulation of dendritic cell function
21. Constitutive class I-restricted exogenous presentation of self antigens in vivo
22. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8 (+) T cells
23. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose
24. CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity
25. A fail-safe mechanism for maintaining self-tolerance
26. In vivo induction of antigen-specific transplantation tolerance to Qa1a by exposure to alloantigen in the absence of T-cell help
27. Three-cell-type clusters of T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response
28. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help
29. CD40-CD40 ligand
30. CD40 ligation in B cell activation, isotype switching and memory development
31. Memory B cell development but not germinal center formation is impaired by in vivo blockade of CD40-CD40 ligand interaction
32. CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection
33. A conditioned dendritic cell can be a temporal bridge between a CD4 (+) t-helper and a t-killer cell
34. T-cell help for cytotoxic T-lymphocytes is mediated by CD40-CD40L interactions
35. Help for cytotoxic-T-cell responses is mediated by CD40 signaling
36. Functional role of CD40 and its ligand
37. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
38. Polyriboinosinic polyribocytidylic acid (poly (I:C)) induces stable maturation of functionally active human dendritic cells
39. Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology
40. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues
41. CD40L blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation
42. Blockade of CD40-CD40 ligand pathway induces tolerance in murine contact hypersensitivity
43. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand
44. Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand
45. Improved skin allograft tolerance induced by treatment with donor splenocytes and an extended course of anti-CD154 monoclonal antibody
46. Mucosally induced systemic T cell unresponsiveness to ovalbumin requires CD40 ligand-CD40 interactions
47. CTLA-4 is required for the induction of high dose oral tolerance
48. Lack of orally induced systemic unresponsiveness in IFN-gamma knockout mice
49. Intranasally induced immunological tolerance is determined by characteristics of the draining lymph nodes: Studies with OVA and human cartilage gp-39
50. Developmental regulation of vascular addressin expression: A possible role for site-associated environments
51. Expanding dendritic cells in vivo enhances the induction of oral tolerance
52. Antigen acquisition by dendritic cells: Intestinal dendritic cells acquire antigen administered orally and can prime naive T cells in vivo
53. A Discrete Subpopulation of Dendritic Cells Transports Apoptotic Intestinal Epithelial Cells to T Cell Areas of Mesenteric Lymph Nodes
54. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen presenting cells that secrete IL-10
55. Interleukin-10-deficient mice develop chronic enterocolitis
56. Reciprocal control of T helper cell and dendritic cell differentiation
57. Peptide-induced antiviral protection by cytotoxic T cells
58. Priming of influenza virus-specific cytotoxic T lymphocytes vivo by short synthetic peptides
59. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide
60. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
61. Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model
62. T cell priming versus T cell tolerance induced by synthetic peptides
63. Peptide antigen treatment of naive and virus-immune mice: Antigen-specific tolerance versus immunopathology
64. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors
65. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction
66. Induction of cytotoxic T-cell response by optimal-length peptides does not require CD4+ T-cell help
67. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
68. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells
69. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40
70. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation
71. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells
72. Ox-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses
73. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor
74. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
75. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28